OS Therapies (NYSE American: OSTX), a biopharmaceutical research and clinical site specializing in ADC and immunotherapy, has completed a targeted identification of common scientists. The company’s stock opened on the NYSE American on August 1, 2024 under the number CUSIP 68764Y108. On August 5, a new CUSIP 68764Y207 was assigned due to a pre-listing. All other countries under the new CUSIP already identify with the new CUSIPwithout you having to conduct a series of similar or related studies between 1 and 5 August 2024.

OS Therapies (NYSE American: OSTX), a discovery-stage and clinical-stage biopharmaceutical company specializing in ADCs and immunotherapy, has filed a declaration of the identifier CUSIP from its ordinary activities. On August 1, 2024, the company’s additions were registered on the NYSE American under CUSIP 68764Y108. On August 5, a company action had to be received prior to posting and a new CUSIP 68764Y207 assigned. All members of the new CUSIP team have already identified with the new CUSIPsince it has created departments for promotions and similar actions between August 1 and 5, 2024. OS Therapies has requested all participants in the market, especially correspondent companies, to update its registrations.

OS Therapies (NYSE American: OSTX) and ADC are a globally recognized company engaged in the development of CUSIP 대한 설명을 발표했습니다. January 2024, 10/8/2024, NYSE American, CUSIP 68764Y108, listing. 8, 5, 1999, 1999, 1999, 1999, 1999 I selected CUSIP in the current issue of CUSIP2024, September 8, 1, September 5, 2024 OS therapies are generally not available.

OS Therapies (NYSE American: OSTX), a discovery-stage biopharmaceutical company specializing in ADC and immunotherapy, has made a clarification of the identity of CUSIP in its ordinary actions. The company’s actions began trading on the NYSE American on August 1, 2024 under the number CUSIP 68764Y108. On August 5, a new CUSIP 68764Y207 was attributed as a result of a corporate action that could be submitted to the application. All actions under the old CUSIP were originally identified with the new CUSIPwithout the departments requiring effective products for measures or similar measures between 1 and 5 August 2024.

OS Therapies (NYSE American: OSTX), a discovery- and clinical-stage biopharmaceutical company specializing in ADC and immunotherapy, issued a clarification regarding the CUSIP identifier of its common stock. The Company’s shares began trading on the NYSE American on August 1, 2024, under CUSIP 68764Y108. On August 5, a new CUSIP 68764Y207 was assigned due to a pre-listing corporate action. All shares under the old CUSIP are now identified under the new CUSIPwithout any share splits or similar measures taking place between August 1 and 5, 2024. OS Therapies calls on all market participants, especially brokerage firms, to update their records accordingly.